Blinklab
(ASX:BB1)

Mr Brian Leedman is an experienced biotechnology entrepreneur with over 15 years’ experience in the biotechnology industry. Mr Leedman is the founder of ResApp Health Limited where Mr Leedman was the executive director of corporate affairs. ResApp Health Limited was acquired by Pfizer (Aust) Limited in 2022. Mr Leedman is an experienced public company director having formerly been the chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and was a director of Alcidion Corporation Limited, Oncosil Medical Limited and Respiri Limited. Prior to ResApp, Mr Leedman co-founded OncoSil Medical Limited and Biolife Science (QLD) Limited (to be later renamed to Imugene Limited). Mr Leedman previously served for ten years as vice president, investor relations for pSivida Corp. Limited, which was listed on the ASX, Frankfurt and NASDAQ. Mr Leedman was formerly the WA chairman of AusBiotech, the association of biotechnology companies in Australia. Mr Leedman holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia.

Dr. Hendrikus Johannes Boele is an assistant professor at the Department of Neuroscience at Erasmus University Medical Centre, a visiting researcher at Princeton Neuroscience Institute, and the CEO of the Company. Dr Boele obtained his PhD (cum laude) in 2014 at the Department of Neuroscience, Erasmus University Medical Centre. His PhD research was focusing on the neural mechanisms underlying associative and motor learning. After he obtained his Medical Degree at Erasmus Medical Centre in 2018, he started his post-doctoral fellowship at Princeton University in the laboratory of Samuel S.-H. Wang, where he was working on brain development and autism. Dr Boele has always been pushing scientific and methodological boundaries, which were awarded over the last five years with over $3.5M USD in funding from top-tier institutes (Princeton University, Erasmus MC), the Dutch Research Counsel, the European Research Counsel, the New Jersey Autism Center for Excellence and prestigious Vidi grant (received in May 2023). Together with his colleague S.K.E. Koekkoek, he has drastically improved the experimental procedures for eyeblink conditioning. In 2018, Dr Boele together with other co-founders of the Company, completed development of the first version of the neurometric testing smart phonebased application. In 2020 the medical application was awarded funding from Princeton Accelerator fund and successfully completed first pilot study in humans. As the initiator and founder of BlinkLab, it is Dr Boele’s strong ambition to bridge the gap between fundamental knowledge of neural processes and clinical application, with a utility that could effectively enhance diagnostics in patients with neurodevelopmental and neuropsychiatric disorders.